161 related articles for article (PubMed ID: 36528041)
21. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.
Nagai S; Chau LC; Schilke RE; Safwan M; Rizzari M; Collins K; Yoshida A; Abouljoud MS; Moonka D
Gastroenterology; 2018 Nov; 155(5):1451-1462.e3. PubMed ID: 30056096
[TBL] [Abstract][Full Text] [Related]
22. Model for end-stage liver disease and model for end-stage liver disease-Na scores predict both before-listing and wait-list mortality.
Yamashiki N; Sugawara Y; Tamura S; Kaneko J; Nojiri K; Aoki T; Sakamoto Y; Hasegawa K; Koike K; Kokudo N
Transplant Proc; 2012 Mar; 44(2):389-92. PubMed ID: 22410024
[TBL] [Abstract][Full Text] [Related]
23. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
Starlinger P; Ahn JC; Mullan A; Gyoeri GP; Pereyra D; Alva-Ruiz R; Hackl H; Reiberger T; Trauner M; Santol J; Simbrunner B; Mandorfer M; Berlakovich G; Kamath PS; Heimbach J
Hepatology; 2021 Sep; 74(3):1533-1545. PubMed ID: 33786862
[TBL] [Abstract][Full Text] [Related]
24. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
Kwong AJ; Lai JC; Dodge JL; Roberts JP
Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
[TBL] [Abstract][Full Text] [Related]
25. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
Abdallah MA; Kuo YF; Asrani S; Wong RJ; Ahmed A; Kwo P; Terrault N; Kamath PS; Jalan R; Singal AK
J Hepatol; 2021 Jun; 74(6):1355-1361. PubMed ID: 33326814
[TBL] [Abstract][Full Text] [Related]
26. Improving the Model for End-Stage Liver Disease with sodium by incorporating kidney dysfunction types.
Cullaro G; Verna EC; McCulloch CE; Lai JC
Hepatology; 2022 Sep; 76(3):689-699. PubMed ID: 35298079
[TBL] [Abstract][Full Text] [Related]
27. Revising model for end-stage liver disease from calendar-time cross-sections with correction for selection bias.
de Ferrante HC; van Rosmalen M; Smeulders BML; Vogelaar S; Spieksma FCR
BMC Med Res Methodol; 2024 Feb; 24(1):51. PubMed ID: 38419019
[TBL] [Abstract][Full Text] [Related]
28. Region 11 MELD Na exception prospective study.
Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
[TBL] [Abstract][Full Text] [Related]
29. MELD 3.0 for adolescent liver transplant candidates.
Kwong AJ; Zhang KY; Ebel N; Mannalithara A; Kim WR
Hepatology; 2023 Aug; 78(2):540-546. PubMed ID: 36943091
[TBL] [Abstract][Full Text] [Related]
30. Survival Benefit of Living-Donor Liver Transplant.
Jackson WE; Malamon JS; Kaplan B; Saben JL; Schold JD; Pomposelli JJ; Pomfret EA
JAMA Surg; 2022 Oct; 157(10):926-932. PubMed ID: 35921119
[TBL] [Abstract][Full Text] [Related]
31. Comparison of transient elastography and Model for End-Stage Liver Disease-sodium to Model for End-Stage Liver Disease-sodium alone to predict mortality and liver transplantation.
Trivedi HD; Danford CJ; Iriana S; Ochoa-Allemant P; Rourke M; Yang KC; Curry MP; Lai M
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e753-e757. PubMed ID: 34231523
[TBL] [Abstract][Full Text] [Related]
32. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate.
Myers RP; Shaheen AA; Aspinall AI; Quinn RR; Burak KW
J Hepatol; 2011 Mar; 54(3):462-70. PubMed ID: 21109324
[TBL] [Abstract][Full Text] [Related]
33. Correcting the sex disparity in MELD-Na.
Wood NL; VanDerwerken D; Segev DL; Gentry SE
Am J Transplant; 2021 Oct; 21(10):3296-3304. PubMed ID: 34174151
[TBL] [Abstract][Full Text] [Related]
34. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation.
Leise MD; Kim WR; Kremers WK; Larson JJ; Benson JT; Therneau TM
Gastroenterology; 2011 Jun; 140(7):1952-60. PubMed ID: 21334338
[TBL] [Abstract][Full Text] [Related]
35. Disparities in liver transplantation before and after introduction of the MELD score.
Moylan CA; Brady CW; Johnson JL; Smith AD; Tuttle-Newhall JE; Muir AJ
JAMA; 2008 Nov; 300(20):2371-8. PubMed ID: 19033587
[TBL] [Abstract][Full Text] [Related]
36. External Validation of the VOCAL-Penn Cirrhosis Surgical Risk Score in 2 Large, Independent Health Systems.
Mahmud N; Fricker Z; Panchal S; Lewis JD; Goldberg DS; Kaplan DE
Liver Transpl; 2021 Jul; 27(7):961-970. PubMed ID: 33788365
[TBL] [Abstract][Full Text] [Related]
37. Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list.
Myers RP; Tandon P; Ney M; Meeberg G; Faris P; Shaheen AA; Aspinall AI; Burak KW
Liver Int; 2014 Sep; 34(8):1176-83. PubMed ID: 24256642
[TBL] [Abstract][Full Text] [Related]
38. Center-related Bias in MELD Scores Within a Liver Transplant UNOS Region: A Call for Standardization.
Verna EC; Connelly C; Dove LM; Adem P; Babic N; Corsetti J; Faix J; Hayden JA; Lifshitz M; Stotler B; Jin Z; Mohan S; Emond JC; Hod EA; Kratz A
Transplantation; 2020 Jul; 104(7):1396-1402. PubMed ID: 31651793
[TBL] [Abstract][Full Text] [Related]
39. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation.
Lai JC; Covinsky KE; Hayssen H; Lizaola B; Dodge JL; Roberts JP; Terrault NA; Feng S
Liver Int; 2015 Sep; 35(9):2167-73. PubMed ID: 25644788
[TBL] [Abstract][Full Text] [Related]
40. High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease.
Reddy KR; O'Leary JG; Kamath PS; Fallon MB; Biggins SW; Wong F; Patton HM; Garcia-Tsao G; Subramanian RM; Thacker LR; Bajaj JS;
Liver Transpl; 2015 Jul; 21(7):881-8. PubMed ID: 25845966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
